BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
A stock expert still thinks Nektar Therapeutics is a good company and believes its stock could be worth $178 per share. When an expert keeps the same positive opinion, it suggests they see reasons to stay confident in the company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.